Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Duke University
Emory University
NeoImmuneTech
M.D. Anderson Cancer Center
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Providence Health & Services
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
University of California, Davis
Takeda
Big Ten Cancer Research Consortium
HUYABIO International, LLC.
H. Lee Moffitt Cancer Center and Research Institute
Rutgers, The State University of New Jersey
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Merck Sharp & Dohme LLC
Abramson Cancer Center at Penn Medicine
University of Kentucky
Sanofi
BerGenBio ASA
University of Southern California
Eli Lilly and Company
ImmuneSensor Therapeutics Inc.
Sanofi
BerGenBio ASA
Peter MacCallum Cancer Centre, Australia
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Incyte Corporation
MacroGenics
Celgene
GlaxoSmithKline
Yale University
Incyte Corporation
Trishula Therapeutics, Inc.
NYU Langone Health
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center
Trishula Therapeutics, Inc.
Bank of Cyprus Oncology Centre
Wake Forest University Health Sciences
Alliance for Clinical Trials in Oncology